These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8471428)

  • 21. Pharmacokinetic analysis and uptake of 18F-FBPA-Fr after ultrasound-induced blood-brain barrier disruption for potential enhancement of boron delivery for neutron capture therapy.
    Yang FY; Chang WY; Li JJ; Wang HE; Chen JC; Chang CW
    J Nucl Med; 2014 Apr; 55(4):616-21. PubMed ID: 24525207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Active and passive mechanisms of [fluorine-18] fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study.
    Kubota R; Kubota K; Yamada S; Tada M; Ido T; Tamahashi N
    J Nucl Med; 1994 Jun; 35(6):1067-75. PubMed ID: 8195872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the pharmacokinetics between L-BPA and L-FBPA using the same administration dose and protocol: a validation study for the theranostic approach using [
    Watanabe T; Hattori Y; Ohta Y; Ishimura M; Nakagawa Y; Sanada Y; Tanaka H; Fukutani S; Masunaga SI; Hiraoka M; Ono K; Suzuki M; Kirihata M
    BMC Cancer; 2016 Nov; 16(1):859. PubMed ID: 27821116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experimental boron neutron capture therapy for melanoma: systemic delivery of boron to melanotic and amelanotic melanoma.
    Coderre JA; Glass JD; Packer S; Micca P; Greenberg D
    Pigment Cell Res; 1990 Dec; 3(6):310-8. PubMed ID: 2101931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors.
    Barth RF; Yang W; Al-Madhoun AS; Johnsamuel J; Byun Y; Chandra S; Smith DR; Tjarks W; Eriksson S
    Cancer Res; 2004 Sep; 64(17):6287-95. PubMed ID: 15342417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Macro- and microdistributions of boron drug for boron neutron capture therapy in an animal model.
    Lin YC; Hwang JJ; Wang SJ; Yang BH; Chang CW; Hsiao MC; Chou FI
    Anticancer Res; 2012 Jul; 32(7):2657-64. PubMed ID: 22753723
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and radiation dosimetry of 4-borono-2-[18F]fluoro-D,L-phenylalanine: a target compound for PET and boron neutron capture therapy.
    Ishiwata K; Ido T; Mejia AA; Ichihashi M; Mishima Y
    Int J Rad Appl Instrum A; 1991; 42(4):325-8. PubMed ID: 1850716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron emission tomography and [18F]BPA: a perspective application to assess tumour extraction of boron in BNCT.
    Menichetti L; Cionini L; Sauerwein WA; Altieri S; Solin O; Minn H; Salvadori PA
    Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S351-4. PubMed ID: 19410471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning.
    Kabalka GW; Smith GT; Dyke JP; Reid WS; Longford CP; Roberts TG; Reddy NK; Buonocore E; Hübner KF
    J Nucl Med; 1997 Nov; 38(11):1762-7. PubMed ID: 9374349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorine-18-labeled fluoroboronophenylalanine PET in patients with glioma.
    Imahori Y; Ueda S; Ohmori Y; Kusuki T; Ono K; Fujii R; Ido T
    J Nucl Med; 1998 Feb; 39(2):325-33. PubMed ID: 9476945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro effects of boron-containing compounds upon glioblastoma cells.
    Bailey SF; Kabalka GW; Fuhr JE
    Proc Soc Exp Biol Med; 1997 Dec; 216(3):452-5. PubMed ID: 9402153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective delivery of boron by the melanin precursor analogue p-boronophenylalanine to tumors other than melanoma.
    Coderre JA; Glass JD; Fairchild RG; Micca PL; Fand I; Joel DD
    Cancer Res; 1990 Jan; 50(1):138-41. PubMed ID: 2293547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual control of melanogenesis and melanoma growth: overview molecular to clinical level and the reverse.
    Mishima Y; Kondoh H
    Pigment Cell Res; 2000; 13 Suppl 8():10-22. PubMed ID: 11041353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preloading with L-tyrosine increases the uptake of boronophenylalanine in mouse melanoma cells.
    Papaspyrou M; Feinendegen LE; Müller-Gärtner HW
    Cancer Res; 1994 Dec; 54(24):6311-4. PubMed ID: 7987818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective targeting of boronophenylalanine to melanoma in BALB/c mice for neutron capture therapy.
    Coderre JA; Glass JD; Fairchild RG; Roy U; Cohen S; Fand I
    Cancer Res; 1987 Dec; 47(23):6377-83. PubMed ID: 3677082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Boron neutron capture therapy of anterior chamber melanoma with p-boronophenylalanine.
    Packer S; Coderre J; Saraf S; Fairchild R; Hansrote J; Perry H
    Invest Ophthalmol Vis Sci; 1992 Feb; 33(2):395-403. PubMed ID: 1740371
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro and in vivo evaluation of o-carboranylalanine as a potential boron delivery agent for neutron capture therapy.
    Yong JH; Barth RF; Wyzlic IM; Soloway AH; Rotaru JH
    Anticancer Res; 1995; 15(5B):2033-8. PubMed ID: 8572598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Penetration and binding of L- and D-carboranylalanine in human melanoma spheroids.
    Pettersson OA; Olsson P; Lindström P; Sjöberg S; Carlsson J
    Melanoma Res; 1993 Oct; 3(5):369-76. PubMed ID: 8292895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Local control of subcutaneous murine melanoma xenografts in nude mice by neutron capture therapy.
    Allen BJ; Corderoy-Buck S; Mallesch JL; Crotty K; Moore DE
    Melanoma Res; 1992 Nov; 2(4):253-62. PubMed ID: 1490113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biodistribution of boron compounds in an animal model of human undifferentiated thyroid cancer for boron neutron capture therapy.
    Dagrosa MA; Viaggi M; Rebagliati RJ; Batistoni D; Kahl SB; Juvenal GJ; Pisarev MA
    Mol Pharm; 2005; 2(2):151-6. PubMed ID: 15804189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.